Trending
Related
Biologics Platform
Sep 9, 2026Platform-Based Drug Substance Development: Applying Prior Knowledge Across Modalities
Platform-based drug substance development combines reusable manufacturing knowledge, technologies, materials, and analytical approaches with product-specific customization to reduce risk, accelerate development, and support more predictable scale-up and commercialization across biologic modalities.
Oncolytic Viruses
Sep 17, 2026Manufacturing Oncolytic Viruses: Where Complexity Demands Experience
Mathias Kahl of IDT Biologika explains how the interconnected demands of dose, concentration, purification, potency, biosafety, and commercial supply make product-specific manufacturing strategies essential for oncolytic viruses.
Topics
Nice Insight
Mammalian Cell Culture, Biologics: Market Insight, CDMO Pricing and Competitor Benchmarking
Open access
Antibody–Drug Conjugate, ADC: Market Insight, CDMO Pricing and Competitor Benchmarking
Open access
Sterile Fill Finish: Market Insight, CDMO Pricing and Competitor Benchmarking
Open access
Nice Insight's State of the Industry 2026: Inside the CDMO Landscape
Open access
Active Pharmaceutical Ingredients, API: Market Insight, CDMO Pricing and Competitor Benchmarking
Open access
Oral Solid Dose, OSD: Market Insight, CDMO Pricing and Competitor Benchmarking
Open access
Microbial Fermentation, Biologics: Market Insight, CDMO Pricing and Benchmarking
Open access
Gene Therapy: Market Insight, CDMO Pricing and Competitor Benchmarking
Open access
Cell Therapy: Market Insight, CDMO Pricing and Competitor Benchmarking
Open access
Content Hub
Parasitic Diseases
Nov 6, 2026
Therapeutics and Vaccines for Parasitic Infections: A Quick Overview and Rececnt Advances
Metabolic Disease
Nov 5, 2026
Precision Medicine in Metabolic Disease: Can We Predict Who Responds to Which Therapy?
Sustainability
Oct 30, 2026
How is sustainability shifting from a reporting exercise to a design constraint in manufacturing and development?
Biocatalysis
Sep 28, 2026
When Does Biocatalysis Create the Better Manufacturing Process?
Pathfinder
Oct 2, 2026
Spray-Dried Dispersions vs. Nanocrystals: Which Is Better for Solubility Enhancement?
Heme-Onc
Sep 24, 2026
The Next Generation of Targeted Therapies in Hematologic Malignancies
Multi-Modality CDMO
Sep 24, 2026
The Rise of the Multi-Modality CDMO: Why Clients Need More Than Capacity
Distributor
Oct 26, 2026
Beyond Logistics: How Modern Chemical Distributors Accelerate Pharmaceutical Development
Pathfinder
Sep 25, 2026
Micronization vs. Nanomilling vs. Amorphous Solid Dispersions: Which Is Better for Poorly Soluble Drugs?
Flow Chemistry
Oct 20, 2026
When Flow Chemistry Solves the Manufacturing Problem
API Oversight
Sep 28, 2026
Can Regulatory Reliance Make Global API Oversight More Efficient?
ASDs
Oct 20, 2026
The Evolving Science of Amorphous Solid Dispersions
Allogeneic CAR-T
Sep 18, 2026
Can Allogeneic Cell Therapy Solve the CAR-T Access Problem?
Partner Selection
Aug 28, 2026
How are organizations balancing cost with regulatory, supply chain, and reputational risk when selecting partners or sites?
Site Network
Aug 11, 2026
How Regional Sites in a Global Site Network Combine Local Insight with Global Scale
Technologies
Orthogonal Methods
Oct 22, 2026
Orthogonal Analytics: How Much Characterization Is Enough?
AMT Designation
Sep 23, 2026
AustinPx’s KinetiSol™ Technology Receives FDA Advanced Manufacturing Technology Designation
Genome Engineering
Jun 29, 2026
Aiming for More than Single-Base Corrections: The Technologies Opening the Genome to Therapeutic Cargo
Organ-on-a-Chip
Oct 15, 2026
Why Multi-Organ Chips Are a Manufacturing and Standardization Challenge
Bioprocessing
Oct 9, 2026
Bioprocessing and Capacity Trends: Growth Despite Continued Uncertainty
Data-Driven Mfg
Oct 21, 2026
Data-Driven Manufacturing and Digital Twins Across the Biologics Network
New Technology
Sep 30, 2026
What are the key bottlenecks preventing rapid adoption of novel technologies?
AAV Analytics
Oct 13, 2026
Advancing AAV Gene Therapies Through Analytical Innovation
MPS
Aug 31, 2026
What Will It Take for Organ-on-Chip Data to Replace Animal Studies?
Advanced Therapies
Nonviral Delivery
Oct 5, 2026
Can Nonviral Delivery Change the Economics of Gene Therapy?
ADCs
Oct 8, 2026
How Lessons from Breast Cancer Are Shaping ADC Development Across Solid Tumors
Antibody Data
Oct 26, 2026
Does Antibody Development Have a Data Problem?
AAV Analytics
Oct 13, 2026
Advancing AAV Gene Therapies Through Analytical Innovation
Heme-Onc
Sep 28, 2026
Therapeutic and Diagnostic Advances Benefiting Patients with Hematologic Malignancies
LNP Analytics
Oct 6, 2026
Beyond Particle Size: Building a Complete Analytical Strategy for LNPs
Cell Therapy
Oct 26, 2026
Overcoming Formulation and Fill/Finish Challenges for Cell Therapies
Viral Vectors
Oct 1, 2026
Gene Therapy Manufacturing After the Capacity Boom
CGT Release
Oct 12, 2026
Release Testing as a Cell and Gene Therapy Manufacturing Bottleneck
Preparedness
Aug 20, 2026
Preparing Manufacturing Networks for the Next Pandemic
Distributor
Oct 26, 2026
Beyond Logistics: How Modern Chemical Distributors Accelerate Pharmaceutical Development
Biologics
Sep 1, 2026
Commercial Thinking Begins in Clinical Phases
Thermostable Vaccine
Aug 10, 2026
Thermostable Vaccines and the Future of Global Distribution
Biosimilars
Sep 15, 2026
The Global Division of Labor Behind the Coming Oncology Biosimilar Wave
Partner Selection
Aug 28, 2026
How are organizations balancing cost with regulatory, supply chain, and reputational risk when selecting partners or sites?
ATMP Supply Chain
Aug 13, 2026
Maintaining Resilient Supply Chains for Advanced Therapies
Supply Chain
Aug 19, 2026
Supply Chain Resilience in 2026: Any Progress?
Drug Shortage
Sep 22, 2026
What It Actually Takes to Engineer a Drug Supply Chain Out of Shortage
CDMO
Nov 13, 2025
Efficiency by Design: Meeting the Evolving Challenges of a Maturing Global Biologics Market
Clinical Diversity
Jun 12, 2025
Redefining Access: Embedding Diversity into the Clinical Research Ecosystem
Masked Antibody
Aug 14, 2026
Expanding the Oncology Therapeutic Window Through Masked Antibody Technology
Ovarian Cancer
Apr 21, 2026
Oncolytic Viruses at a Turning Point: Advancing Olvi-Vec for Advanced Ovarian Cancer
CDMO Excellence
Dec 2, 2025
Delivering CDMO Excellence, Quality, and Value through Dedication
Clinical Diversity
Jun 12, 2025
Staying the Course: Sustaining Equity in Clinical Trials Amid Headwinds
Antibodies
Aug 22, 2025
Co-Founders of Biotech Avidicure Talk New Antibody Modality, Starting from Scratch, and $50M Launch
Oncology
Jul 23, 2026
Harnessing Macrophage Biology to Overcome Tumor Immune Evasion
APM
Oct 28, 2025
Raising the Bar in Analytical Excellence: Samsung Biologics’ Approach to Assay Performance Monitoring
Road To Series
